Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5529_Библиотеки_им_академика_М_И_Перельмана
.pdf
274 Bioinformatics of Autoimmune Diseases
upregulation in T cells, and elevated levels of IL2RA protein on the cell surface, providing a comprehensive mechanistic link from chromatin to function.
To functionally test hypotheses derived from multi-omics analyses, CRISPR-based perturbation techniques have become indispensable. CRISPR interference (CRISPRi) or CRISPR activation (CRISPRa) systems allow for targeted repression or activation of putative regulatory elements
without altering the DNA sequence itself, thereby assessing the causal impact of specic enhancers
or promoters on gene expression. In autoimmune disease research, this approach is particularly useful for validating non-coding variants identied by ATAC-Seq and GWAS overlap. For instance,
if a non-coding SNP falls within a T cell–specic enhancer that shows differential accessibility
in lupus patients, CRISPRi can be used to silence this enhancer in primary T cells to determine
whether it affects the expression of nearby immune genes like STAT4 or CXCR5. Such functional
assays are essential for conrming regulatory roles and for prioritizing potential therapeutic targets.
Collectively, these emerging technologies and their integration are ushering in a new era of precision epigenomics, enabling researchers to dissect the molecular underpinnings of autoimmunity
with both cellular specicity and mechanistic depth.
8.6.7 CHALLENGES AND FUTURE DIRECTIONS
Despite the remarkable progress enabled by ATAC-Seq and related technologies, several challenges
remain in the effort to fully unravel the epigenetic architecture of autoimmune diseases. One of the
foremost difculties lies in interpreting non-coding genetic variation associated with disease risk.
GWAS have identied thousands of SNPs linked to autoimmune disorders, yet the vast majority
of these variants fall outside protein-coding regions, often residing within enhancers, silencers,
or other regulatory elements. While ATAC-Seq can help prioritize these regions by highlighting
accessible chromatin landscapes, assigning functional signicance to individual variants remains
a complex task. Variants may affect TF binding motifs, chromatin looping, or the recruitment of
co-factors in subtle, context-dependent ways. Moreover, the same regulatory element may behave
differently across cell types or disease states, requiring sophisticated models that integrate chromatin accessibility with expression, three-dimensional genome architecture, and epigenetic context to
pinpoint causal mechanisms.
Another major obstacle is the inherent plasticity of immune cell states and the technical variation introduced during sample processing and data analysis. Immune cells exist along a dynamic
continuum of activation, differentiation, and exhaustion, especially under the inuence of chronic
inammation seen in autoimmune diseases. ATAC-Seq proles can shift rapidly in response to
external cues, making it difcult to distinguish stable disease-associated epigenetic signatures from
transient, reversible changes. Additionally, technical variation (such as differences in cell isolation
protocols, sequencing depth, or batch effects) can obscure biologically meaningful patterns. This is
particularly problematic when working with clinical samples, where cell viability, treatment status,
and comorbidities introduce additional layers of heterogeneity. Addressing these issues requires
rigorous experimental design, incorporation of controls, and advanced computational tools for batch
correction and normalization, as well as longitudinal sampling strategies that can capture the temporal evolution of chromatin landscapes.
Compounding these challenges is the current lack of comprehensive, autoimmune-specic reference epigenomes. While large-scale consortia such as ENCODE and Roadmap Epigenomics have
generated rich datasets for many cell types, they often rely on healthy donors and do not capture
the unique regulatory environments of inamed tissues, autoimmune lesions, or therapy-resistant
immune cells. This limitation hinders our ability to contextualize chromatin accessibility changes
observed in patient samples and to distinguish disease-specic regulatory features from normal
variation. The eld urgently needs high-resolution reference maps of chromatin states derived from
autoimmune tissues and disease-relevant immune subsets, ideally spanning diverse genetic backgrounds, disease stages, and environmental exposures. Such reference epigenomes would not only
275 ATAC-Seq for Autoimmune Diseases
serve as critical baselines for comparative analysis but also facilitate the identication of biomarkers
and therapeutic targets specic to autoimmune pathophysiology.
Looking forward, the ultimate goal is to move toward personalized epigenetic proling in autoimmunity, where an individual’s chromatin landscape could inform diagnosis, prognosis, and therapeutic decisions. Just as personalized genomics has begun to reshape the management of certain
cancers and rare diseases, personalized epigenomics holds promise for identifying the regulatory
signatures that distinguish responders from non-responders to biologic therapies, or that predict
disease ares before clinical symptoms arise. Achieving this vision will require the integration of
ATAC-Seq with clinical metadata, genetic background, environmental history, and longitudinal
disease tracking. Machine learning approaches capable of handling such multidimensional data will
be essential to build predictive models that are both accurate and interpretable. Although signicant
hurdles remain, the convergence of single-cell technologies, spatial epigenomics, and functional
genomics is setting the stage for a new era in which the epigenetic underpinnings of autoimmunity
are not only mapped but also leveraged to guide personalized, mechanism-based interventions.
8.7 SUMMARY
This chapter provided a comprehensive and multidimensional exploration of ATAC-Seq and its pivotal role in decoding the epigenetic architecture of autoimmune diseases. It began with an overview
of chromatin accessibility and its fundamental importance in gene regulation, particularly within
immune cells, where dynamic chromatin remodeling guides lineage commitment, functional differentiation, and immune response. The chapter established ATAC-Seq as a transformative technique
capable of mapping genome-wide open chromatin regions with high sensitivity, highlighting its advantages over earlier methods like ChIP-Seq, DNase-Seq, and FAIRE-Seq. Applications of ATAC-Seq
in immunology were then explored, demonstrating how changes in chromatin accessibility underlie
pathological processes in autoimmune diseases such as lupus, RA, MS, and T1D. Through detailed
analysis of T cells, B cells, and innate immune populations, the chapter revealed how dysregulated
enhancer activity and TF binding contribute to immune dysfunction and chronic inammation.
The chapter also presented a step-by-step guide to the ATAC-Seq methodology, including sample preparation, experimental design, and detailed descriptions of the computational pipeline for
data preprocessing, peak calling, annotation, and visualization. It emphasized how fragment size
distributions and footprinting techniques can be used to infer nucleosome positioning and TF occupancy, offering deeper insights into regulatory dynamics. The integration of motif enrichment, differential binding analysis using tools like TOBIAS, and visualization with genome browsers further
enriched the interpretive power of ATAC-Seq. Importantly, the chapter addressed practical challenges unique to autoimmune research, such as sample heterogeneity, limited tissue availability, and
the need for high-resolution, cell type–specic data. It concluded by discussing cutting-edge applications such as scATAC-Seq, spatial epigenomics, and CRISPR-based functional validation, which
together open new frontiers for understanding the epigenetic basis of autoimmunity. Altogether, this
chapter positioned ATAC-Seq as a critical tool in the arsenal of modern immunology, capable of
linking chromatin structure to gene regulation and offering novel insights into disease mechanisms
and therapeutic targets.
BIBLIOGRAPHY
Allis, C. D., & Jenuwein, T. (2016). The molecular hallmarks of epigenetic control. Nature Reviews Genetics,
17(8), 487–500. https://doi.org/10.1038/nrg.2016.59
Bach, J. F. (2018). The hygiene hypothesis in autoimmunity: The role of pathogens and commensals. Nature
Reviews Immunology, 18(2), 105–120. https: //do i.o rg/10 .1038/n ri .2017.111
Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone modications. Cell Research,
21(3), 381–395. https://doi.org /10.1038/cr.2011.22
276 Bioinformatics of Autoimmune Diseases
Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., …, & Zhao, K. (2007). High-resolution
proling of histone methylations in the human genome. Cell, 129(4), 823–837. https://doi.org/10.1016/
j.cell.2007.05.009
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013). Transposition of native
chromatin for fast and sensitive epigenomic proling of open chromatin, DNA-binding proteins and
nucleosome position. Nature Methods, 10(12), 1213–1218. https://doi.org/10.1038/nmeth.2688
Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015). ATAC-Seq: A method for assaying chroma-
tin accessibility genome-wide. Current Protocols in Molecular Biology, 109(1), 21.29.1–21.29.9. https://
doi.org /10.1002/0471142727.mb2129s109
Calderon, D., Nguyen, M. L. T., Mezger, A., Kathiria, A., Müller, F., Nguyen, V., …, & Buenrostro, J. D.
(2019). Landscape of stimulation-responsive chromatin across diverse human immune cells. Nature
Genetics, 51(10), 1494–1505. https://doi.org/10.1038/s41588-019-0505-9
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., …, & Majeti, R. (2016).
Lineage-specic and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics, 48(10), 1193–1203. https://doi.org/10.1038/ng.3646
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., …, &
Chang, H. Y. (2017). An improved ATAC-Seq protocol reduces background and enables interrogation of
frozen tissues. Nature Methods, 14(10), 959–962. https://doi.org/10.1038/nmeth.4396
Fasolino, M., et al. (2020). Genetic variation in type 1 diabetes recongures the 3D chromatin organization
of T cells and alters gene expression. Immunity, 52(2), 257–274.e11. https://doi.org/10.1016/j.immuni.
2020.01.003
Floess, S., et al. (2007). Epigenetic control of the foxp3 locus in regulatory T cells. PLOS Biology, 5(2), e38.
https://doi.org/10.1371/journal.pbio.0050038 https://doi.org/10.1371/journal.pbio.0050038
Fujiwara, T., Takahashi, K., Okada, Y., & Nakayama, T. (2019). High-quality ATAC-seq data recovered from
cryopreserved breast cell lines and tissue samples. Scientic Reports, 9, 516. https://doi.org/10.1038/
s41598-018-36927-7
Garg, G., et al. (2012). Type 1 diabetes–associated IL2RA variation lowers IL-2 signaling and contributes to
diminished CD4
+
CD25+ regulatory T-cell function. Journal of Immunology, 188(9), 4644–4653. https://
doi.org/10.4049/jimmunol.1100272
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., …, & Glass, C. K. (2010). Simple combi-
nations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular Cell, 38(4), 576–589. https://doi.org/10.1016/j.molcel.2010.05.004
Klemm, S. L., Shipony, Z., & Greenleaf, W. J. (2019). Chromatin accessibility and the regulatory epigenome.
Nature Reviews Genetics, 20(4), 207–220. https://doi.org/10.1038/s41576-018-0089-8
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia,
J., Rozenblatt-Rosen, O., Kuchroo, V. K., Regev, A., & Anderson, A. C. (2019). Checkpoint Blockade
Immunotherapy Induces Dynamic Changes in PD-1- CD8
+
Tumor-Inltrating T Cells. Immunity, 50(1),
181-194.e6. ht t ps://doi.org /10.1016/j.immuni.2018.11.014
Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., et al. (2014). Chromatin state dynamics during blood forma-
tion. Science, 345(6199), 943–949. https://doi.org/10.1126/science.1256271
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997). Crystal structure of the
nucleosome core particle at 2.8 Å resolution. Nature, 389(6648), 251–260. https://doi.org/10.1038/38444
Mazzone, R., Zwergel, C., Artico, M., Taurone, S., Ralli, M., Greco, A., & Mai, A. (2019). The emerging role
of epigenetics in human autoimmune diseases. Clinical Epigenetics, 11, 128. https://doi.org/10.1186/
s13148-019-0632-2
Meers, M. P., Bryson, T. D., Henikoff, J. G., & Henikoff, S. (2019). Improved CUT&Tag chromatin proling
tools. eLife, 8, e46314. https://doi.org/10.7554/eLife.46314
Mumbach, M. R., Satpathy, A. T., Boyle, E. A., Dai, C., Gowen, B. G., Cho, S. W., …, & Chang, H. Y. (2017).
Enhancer connectome in primary human cells identies target genes of disease-associated DNA elements. Nature Genetics, 49(11), 1602–1612. https://doi.org/10.1038/ng.3963
Peters, T. J., Buckley, M. J., Statham, A. L., Pidsley, R., Samaras, K., Lord, R. V., & Clark, S. J. (2020). De
novo identication of differentially methylated regions in the human genome. Epigenetics & Chromatin,
8, Article 6. https://doi.org/10.1186/1756-8935-8-6
Preissl, S., Fang, R., Huang, H., Zhao, Y., Raviram, R., Gorkin, D. U., …, & Ren, B. (2018). Single-nucleus
analysis of accessible chromatin in developing mouse forebrain reveals cell-type-specic transcriptional regulation. Nature Neuroscience, 21(3), 432–439. https://doi.org/10.1038/s41593-018-0079-3
Samstein, R. M., Josefowicz, S. Z., Arvey, A., Treuting, P. M., & Rudensky, A. Y. (2012). Extrathymic genera-
tion of regulatory T cells in placental mammals mitigates maternal-fetal conict. Cell, 150(1), 29–38.
https://doi.org/10.1016/j.cell.2012.05.031
277 ATAC-Seq for Autoimmune Diseases
Satpathy, A. T., Granja, J. M., Yost, K. E., Qi, Y., Meschi, F., McDermott, G. P., …, & Chang, H. Y. (2019).
Massively parallel single-cel l ch romatin landscape s of hu man immune cell development and intrat umoral
T cell exhaustion. Nature Biotechnology, 37(8), 925–936. https://doi.org/10.1038/s41587-019-0206-z
Scharer, C. D., Blalock, E. L., Mi, T., et al. (2019). Epigenetic programming underpins B cell dysfunction in
human SLE. Nature Immunology, 20(8), 1071–1082. https://doi.org/10.1038/s41590-019-0419-9
Schmidl, C., Klug, M., Boeld, T. J., Andreesen, R., Hoffmann, P., Edinger, M., & Rehli, M. (2009). Lineage-
specic DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome
Research, 19(7), 1165–1174. https://doi.org/10.1101/gr.091470.109
Shih, H. Y., Sciume, G., Mikami, Y., et al. (2014). Developmental acquisition of regulomes underlies innate
lymphoid cell functionality. Cell, 156(5), 847–860. https://doi.org/10.1016/j.cell.2014.01.040
Van Der Byl, W., Nüssing, S., Peters, T. J., Ahn, A., Li, H., Ledergor, G., … Parish, I. A. (2024). The CD8
+
T
cell tolerance checkpoint triggers a distinct differentiation state dened by protein translation defects.
Immunity, 57(6), 1324–1344.e8. https://doi.org/10.1016/j.immuni.2024.04.026
Yosef, N., Shalek, A. K., Gaublomme, J. T., et al. (2013). Dynamic regulatory network controlling TH17 cell
differentiation. Nature, 496(7446), 461–468. https://doi.org/10.1038/nature11981
Zhang, F., et al. (2019). Dening inammatory cell states in rheumatoid arthritis joint synovial tissues by inte-
grating single-cell transcriptomics and mass cytometry. Nature Immunology, 20(7), 928–942. https://
doi.org/10.1038/s41590 - 019-0378-1
Zhou, Y., Reiser, M., Krawczyk, C., et al. (2018). Epigenetic control of CD8
+
T cell differentiation. Nature
Reviews Immunology, 18(5), 340-356. https://doi.org/10.1038/nri.2017.146
Roles of Bacteria in
9
Autoimmune Diseases
9.1 INTRODUCTION
Bacteria are diverse, single-celled microorganisms that inhabit nearly every environment on Earth,
including the human body. They are categorized into numerous taxonomic families based on
genetic, structural, and metabolic characteristics. In the context of human health, several major
bacterial families play pivotal roles, both benecial and detrimental. The Lactobacillaceae and
Bidobacteriaceae, for instance, are known for their benecial contributions to gut health, including digestion, production of vitamins, and modulation of immune responses. Conversely, families
such as Enterobacteriaceae, Clostridiaceae, and Streptococcaceae include pathogenic members
that can cause infections and contribute to immune dysregulation under certain conditions.
The pathogenicity of bacteria refers to their capacity to cause disease, which may arise from
toxin production, tissue invasion, or manipulation of the host immune response. Pathogenic
bacteria often possess specialized virulence factors, such as adhesins, invasins, and immuneevasive proteins, that facilitate colonization of host tissues and help evade immune clearance. For
instance, Helicobacter pylori, a member of the Helicobacteraceae family, produces urease and
cytotoxins (such as CagA and VacA) that damage the gastric epithelium, contributing to peptic
ulcers and increasing the risk of gastric cancer. Likewise, strains of Escherichia coli can range
in pathogenic potential, with some causing mild gastrointestinal symptoms and others leading to
severe systemic infections by hijacking host cellular processes and disrupting immune signaling
pathways.
The human immune system responds to bacterial invasion through a multilayered defense mechanism involving both innate and adaptive components. Pattern recognition receptors (PRRs), such
as Toll-like receptors (TLRs), detect conserved microbial-associated molecular patterns (MAMPs),
including lipopolysaccharides (LPSs) on Gram-negative bacteria and peptidoglycans on Gram-
positive species. Upon recognition, these receptors initiate intracellular signaling cascades that
result in the production of cytokines and chemokines, which recruit immune cells to the site of
infection and promote inammation. Antigen-presenting cells (APCs) process bacterial antigens
and present them via major histocompatibility complex (MHC) molecules to T cells, thereby activating the adaptive immune response. This response includes the production of pathogen-specic
antibodies by B cells and the activation of cytotoxic T lymphocytes, both of which contribute to the
clearance of the invading microbes.
However, this protective response can sometimes become dysregulated. In autoimmune diseases,
certain bacterial components may mislead the immune system into targeting the body’s own tissues. This can occur through mechanisms such as molecular mimicry, in which bacterial antigens
closely resemble host proteins, leading to cross-reactive immune responses. Alternatively, chronic
immune activation may result from persistent bacterial presence or disruption of mucosal barriers,
ultimately contributing to sustained inammation and autoimmunity.
In the broader context of human health, the balance between benecial and harmful bacteria,
often referred to as eubiosis and dysbiosis, respectively, is crucial for maintaining immune homeostasis. Benecial microbes contribute to the development of immune tolerance and the suppression
of inappropriate inammatory responses. When this balance is disrupted, whether due to infection,
antibiotic use, or environmental factors, it can tip the immune system toward chronic activation and
aut oi mm un ity.
278 DO I: 10 .1201/9 7810 0 36 85432-9
279 Roles of Bacteria in Autoimmune Diseases
The relationship between autoimmune diseases and the bacterial communities that reside in the
human body, particularly in the gut, has become a focal point of biomedical research in recent years.
This interaction is grounded in the concept of the human microbiome, an ecosystem of commensal,
symbiotic, and occasionally pathogenic microorganisms that inhabit various niches of the body.
The immune system has evolved in constant dialogue with this microbiota, learning to distinguish
between harmless microbes and true pathogens. However, when this balance is disrupted (dysbiosis), the immune system may begin to misinterpret self-antigens as foreign, leading to chronic
inammation and autoimmunity.
One well-documented example is the link between gut dysbiosis and rheumatoid arthritis (RA).
Studies have shown that patients with RA often exhibit signicant alterations in their gut microbiota
composition. For instance, Prevotella copri has been reported to be enriched in the guts of newonset RA patients. Research by Scher et al. (2013) found that P. copri not only correlated with RA
development but also inuenced systemic immune responses, including the induction of T helper
17 (Th17) cells, a Th cell subset involved in autoimmune inammation. Moreover, animal models
colonized with P. copri developed more severe arthritis, indicating a potential causative role.
In multiple sclerosis (MS), an autoimmune disorder affecting the central nervous system, similar microbial associations have been observed. Several studies have reported a reduction in shortchain fatty acid (SCFA)-producing bacteria, such as Faecalibacterium prausnitzii, in individuals
with MS. SCFAs (particularly butyrate) are known to support intestinal epithelial barrier integrity
and promote the differentiation of regulatory T cells (Tregs), which are essential for maintaining
immune tolerance. The depletion of such protective commensals may therefore contribute to the loss
of immune regulation and exacerbate autoimmune pathology in MS (Cekanaviciute et al., 2017).
Type 1 diabetes (T1D) provides further evidence for the role of the microbiome in autoimmunity. Longitudinal studies of children at genetic risk for T1D, such as those conducted by the
TEDDY (The Environmental Determinants of Diabetes in the Young) project, have demonstrated
that the appearance of islet autoantibodies is often preceded by a decline in microbial diversity
and an expansion of pro-inammatory taxa, including Bacteroides dorei. These microbial shifts
are believed to disrupt gut barrier function (a phenomenon commonly referred to as “leaky gut”),
allowing bacterial components such as LPSs to enter systemic circulation and potentially initiate
autoimmune responses against pancreatic beta cells (Vatanen et al., 2018).
In systemic lupus erythematosus (SLE), increasing evidence supports a role for bacterial translocation and molecular mimicry in disease pathogenesis. In particular, peptides derived from
Enterococcus gallinarum have been shown in mouse models to translocate from the gut to systemic organs such as the liver, where they trigger autoantibody production and systemic inammation. These ndings are mirrored in human studies, in which E. gallinarum DNA and associated
immune signatures have been detected in tissues outside the gut, suggesting a translocation-driven
mechanism that contributes to the loss of immune tolerance and promotes autoimmunity (Manfredo
Vieira et al., 2018).
Collectively, these ndings illustrate that the bacterial community does not merely coexist with
the human host but actively shapes immune regulation. Perturbations in microbiota composition,
diversity, and function can act as environmental triggers for genetically susceptible individuals,
inuencing the onset, progression, and severity of autoimmune diseases. This growing body of
evidence supports the idea that microbiome-targeted interventions, such as prebiotics, probiotics,
or even fecal microbiota transplantation, may hold promise in modulating immune responses and
treating or preventing autoimmune disorders.
9.2 BACTERIA AND AUTOIMMUNITY
Bacteria play a signicant role in both the onset and progression of autoimmune diseases in humans
through a range of distinct yet interconnected mechanisms. These interactions can disrupt immune
tolerance, trigger inappropriate immune responses, and create an environment conducive to chronic
280 Bioinformatics of Autoimmune Diseases
inammation. In the following sections, we examine the key molecular and immunological pathways by which bacterial agents may initiate or exacerbate autoimmunity in human hosts.
9.2.1 MOLECULAR MIMICRY
Molecular mimicry is a well-established immunological phenomenon in which structural similarities between microbial antigens and host proteins trigger an immune response that inadvertently
targets self-tissues. This mechanism is considered a key contributor to the pathogenesis of several
autoimmune diseases. During T-cell development in the thymus, immature T cells undergo a selection process to ensure they can distinguish between self and non-self. Most T cells with T-cell
receptors (TCRs) that bind strongly to self-antigens (the body’s own proteins or peptides presented
by MHC molecules) are eliminated through a process known as central tolerance. However, some
autoreactive T cells, which possess TCRs that can bind weakly to self-antigen–MHC complexes,
may escape deletion and enter the peripheral immune system. Under normal conditions, these cells
remain inactive, but they can become activated if they encounter foreign peptides that closely mimic
the structure of self-peptides.
At the molecular level, pathogen-derived peptides may resemble self-antigens closely enough (in
either amino acid sequence or three-dimensional structure) to bind the same MHC molecules and be
recognized by autoreactive TCRs. Studies involving peptide alignment, MHC-binding prediction,
and structural modeling have demonstrated this type of mimicry in several autoimmune conditions.
For example, in MS, viral peptides from Epstein-Barr virus (EBV) are thought to mimic myelin
basic protein (MBP), a key self-antigen in the central nervous system, potentially triggering autoimmune attacks on myelin. Likewise, in Guillain-Barré syndrome, structural similarity between
Campylobacter jejuni antigens and peripheral nerve gangliosides can elicit cross-reactive immune
responses. These mimicry events break immune tolerance and initiate tissue-specic autoimmunity.
From a genomic perspective, high-throughput sequencing technologies have enabled a detailed
investigation into the repertoire of TCRs and B-cell receptors (BCRs) involved in autoimmune processes. Whole-exome sequencing and RNA Sequencing (RNA-Seq) have revealed somatic mutations
and gene expression alterations in regulatory pathways that compromise immune tolerance. For
instance, genes such as autoimmune regulator (AIRE), PTPN22, and FOXP3, which are crucial for
immune regulation and self-tolerance, are often found to be mutated or downregulated in patients
with autoimmune conditions. In the context of molecular mimicry, pathogens may trigger epigenetic changes or activate transposable elements, further enhancing the likelihood of autoimmune
reactivity by modifying the antigen presentation machinery or co-stimulatory signals.
At the proteomic level, mass spectrometry-based immunopeptidomics has been instrumental in
identifying self and non-self peptides presented by MHC molecules. In autoimmune diseases such
as T1D and SLE, specic autoantigens such as insulin, GAD65, and Ro/SSA have been shown to
share epitopes with microbial proteins. Protein microarrays have also revealed autoantibody signatures that correspond to microbial homologs, supporting the mimicry hypothesis. Proteomic analyses in inamed tissues and lymphoid organs have detected altered expression and post-translational
modications, such as citrullination and acetylation, which may further increase molecular mimicry by changing self-proteins into immunogenic forms.
On the pathway level, mimicry-induced autoimmunity involves dysregulation of key signaling cascades such as the NF-κB, JAK-STAT, and MAPK pathways, which govern inammation,
cytokine production, and immune cell differentiation. Studies in experimental models and patientderived samples have demonstrated that mimicry can lead to persistent activation of these pathways,
culminating in chronic inammation and tissue destruction. For example, in MS, MBP mimics
found in EBV can lead to sustained activation of autoreactive T cells via the IL-23/Th17 axis, a
pathway heavily implicated in many autoimmune diseases. Moreover, activation of TLRs by microbial components can act as adjuvants that break immune tolerance, intensifying the autoimmune
response initiated by mimicry.
281 Roles of Bacteria in Autoimmune Diseases
9.2.2 BYSTANDER ACTIVATION
A critical link between infection and the onset of autoimmunity lies in a phenomenon known as
bystander activation. This process occurs when an immune response aimed at eliminating a pathogen inadvertently activates self-reactive lymphocytes (immune cells capable of attacking the body’s
own tissues). Unlike classical autoimmunity, which arises from direct recognition of self-antigens,
bystander activation reects a failure in immune regulation triggered by intense, non-specic
inammation. It represents a mechanism by which a localized and protective immune response
may escalate into a broader, self-destructive process.
Bystander activation frequently arises during infections, particularly in mucosal sites with constant microbial exposure, such as the gastrointestinal tract and oral cavity. In these settings, innate
immune cells, including macrophages and dendritic cells, recognize invading pathogens through
PRRs that detect conserved microbial components known as pathogen-associated molecular patterns (PAMPs). This recognition initiates an inammatory cascade characterized by the release
of pro-inammatory cytokines such as interleukin-1β (IL-1β), IL-6, tumor necrosis factor-alpha
(TNF-α), and various interferons. These cytokines play essential roles in recruiting and activating
adaptive immune cells, especially T lymphocytes, to eliminate the invading microbe.
However, this heightened inammatory environment can also have unintended consequences.
Autoreactive T cells, T lymphocytes that escaped deletion during thymic selection and can recognize self-antigens, typically remain quiescent under normal physiological conditions. Yet, during intense inammation, these cells may receive sufcient stimulation to become activated, not
because they recognize the pathogen itself, but due to the abundant cytokines and upregulated
co-stimulatory molecules (such as CD80 and CD86) expressed by activated APCs. Once activated,
these autoreactive T cells can proliferate, differentiate into effector cells, and initiate tissue damage
by recognizing self-peptides presented by MHC molecules in inamed tissues.
The implications of this mechanism are particularly concerning when the target tissues are vital
for physiological function. In T1D, autoreactive T cells attack the insulin-producing β-cells of the
pancreatic islets. In RA, they inltrate and iname the synovial joints. In MS, they damage the
myelin sheath that insulates neurons. Each of these autoimmune diseases has shown clinical or
molecular links to prior infections, suggesting that bystander activation may act as a critical initiating or amplifying factor.
Evidence supporting bystander activation is particularly strong in studies of the gastrointestinal
tract. The gut harbors a dense and diverse microbial ecosystem that plays a key role in immune
education and tolerance. However, microbial imbalance (dysbiosis) can lead to chronic, low-grade
inammation. This inamed environment may activate nearby autoreactive T cells, particularly in
genetically susceptible individuals. If the epithelial barrier becomes compromised, bacterial components like LPS can leak into circulation, spreading systemic inammation and increasing the
likelihood of autoreactive immune activation in distant organs.
A similar process has been observed in chronic oral infections. For instance, Porphyromonas
gingivalis, a keystone bacterium in periodontitis, not only triggers robust inammatory responses
but also modies host proteins through citrullination, creating neoantigens that the immune system
may mistakenly recognize as foreign. The resulting cytokine storm can activate self-reactive T cells,
contributing to the development or exacerbation of systemic autoimmune diseases such as RA.
Chronic infections pose an even greater risk for bystander activation due to their prolonged
inammatory signaling. Sustained production of cytokines and repeated immune cell recruitment increase the probability of losing self-tolerance. Compounding this risk is the impact on
regulatory T cells (Tregs), which are essential for suppressing inappropriate immune responses.
Inammatory cytokines such as IL-6 and TNF-α can impair Treg function or shift the immune
balance toward pro-inammatory Th17 cells. In some cases, microbial signals can destabilize
Tregs, stripping them of their suppressive phenotype and allowing them to contribute directly to
tissue damage.
282 Bioinformatics of Autoimmune Diseases
At the molecular level, bystander activation is not solely driven by cytokines but also by enhanced
co-stimulatory signaling. In non-lymphoid tissues undergoing inammation, APCs upregulate
CD80 and CD86, which engage CD28 receptors on T cells. Even autoreactive T cells that were
previously below the activation threshold can be pushed into full activation when exposed to this
heightened signaling.
Recent advances in single-cell genomics and transcriptomics further validate this model. In
autoimmune-affected tissues, researchers have identied expanded T-cell clones with TCRs that
do not correspond to known pathogenic antigens, indicating activation independent of the initiating
infection. Proteomic analyses reveal cytokine proles consistent with broad immune activation,
and pathway enrichment often highlights NF-κB signaling, interferon responses, and cellular stress
pathways, hallmarks of a non-specic but highly inammatory immune landscape.
9.2.3 DISRUPTION OF EPITHELIAL BARRIERS
The epithelial barriers of the body, especially within the gastrointestinal tract, serve as critical
frontlines between the external environment and the internal immune system. These barriers are
made up of a single layer of tightly connected epithelial cells, held together by specialized junctions
(tight junctions, adherens junctions, and desmosomes). Their role is to regulate the passage of nutrients and immune signals while preventing harmful microbes and their components from entering
deeper tissues. When these barriers become compromised, a condition often referred to as “leaky
gut”, microbial products such as LPS, agellin, and peptidoglycans can cross the epithelium and
enter the lamina propria or even the bloodstream. These microbial components are recognized by
the immune system as PAMPs. Once detected, they trigger inammatory responses that can disrupt
immune tolerance and promote systemic immune activation.
Among these microbial signals, LPS, a component of the outer membrane of Gram-negative
bacteria, is particularly potent. When LPS enters circulation, it binds to Toll-like receptor 4 (TLR4)
on innate immune cells, especially macrophages and dendritic cells. This interaction activates key
inammatory pathways, including NF-κB and interferon regulatory factors, which drive the production of pro-inammatory cytokines like TNF-α, IL-6, and IL-1β.
Under normal conditions, the mucosal immune system coexists peacefully with gut microbes,
responding only to pathogens. However, sustained exposure to LPS and similar molecules due to
barrier dysfunction can overwhelm these regulatory mechanisms. The result is chronic inammation and loss of immune tolerance, two hallmarks of autoimmune disease. This pathway has been
implicated in several conditions, including SLE, T1D, and inammatory bowel disease (IBD).
In SLE, elevated blood levels of endotoxins like LPS are commonly observed and have been
linked to increased gut permeability. Patients often show reduced expression of tight junction
proteins such as occludin and claudins, which are essential for maintaining the epithelial barrier.
These disruptions allow microbial products to enter systemic circulation and continuously stimulate
the immune system. Dendritic cells exposed to these signals can present both microbial and selfantigens to naïve T cells, triggering the activation of autoreactive T cells and B cells. This process
not only sustains inammation but also contributes to the production of autoantibodies against
nuclear components, a dening feature of lupus.
Similarly, in T1D, a leaky gut is thought to expose the immune system to bacterial products
that can initiate or accelerate the autoimmune destruction of insulin-producing beta cells. Children
with recent-onset T1D often show increased intestinal permeability and reduced levels of secretory
Immunoglobulin A (IgA) or sIgA, a protective antibody involved in mucosal immunity. Bacterial
components that cross the gut barrier can reach the pancreatic lymph nodes, where they may activate self-reactive T cells. These T cells can then migrate to the pancreas and damage beta cells.
Evidence from non-obese diabetic (NOD) mouse models supports this mechanism: restoring gut
barrier integrity through probiotics or SCFAs like butyrate helps reinforce tight junctions and
reduce inammation, thereby delaying or even preventing disease onset.
283 Roles of Bacteria in Autoimmune Diseases
Epithelial barrier disruption is not limited to autoimmune diseases. It is also involved in metabolic syndromes, neuroinammatory conditions, and allergic disorders. What connects these
diverse conditions is persistent low-grade inammation driven by microbial signals that escape the
gut and enter systemic circulation. This has led researchers to view the gastrointestinal tract not just
as a digestive organ, but as a central regulator of systemic immune health.
The health of the epithelial barrier is shaped by many factors: host genetics, diet, microbiome
composition, and environmental exposures. Diets high in fat, low in ber, or rich in emulsiers can
disturb the microbiota and erode the protective mucus layer, weakening the epithelium. Likewise,
antibiotic use, chronic infections, and psychological stress have all been shown to impair epithelial
integrity by damaging the molecular components of tight junctions.
At the molecular level, barrier disruption often corresponds with decreased levels of structural
proteins like claudin-1, ZO-1, and occludin, which are regulated by cytokines such as TNF-α and
IFN-γ. Inammation can therefore both cause and result from barrier loss, creating a self-reinforcing
cycle that accelerates disease. Immune cells like innate lymphoid cells (ILCs), Paneth cells, and
goblet cells also contribute by producing antimicrobial peptides and mucus. Dysfunction in any of
these cell types (whether due to genetic mutation or microbial imbalance) can further weaken the
barrier and expose underlying immune tissues to microbial stimuli.
Recent advances in transcriptomics, single-cell analysis, and spatial proling have allowed
researchers to trace how barrier breakdown occurs and how it shapes immune responses over
time. For example, even subtle early disruptions in the epithelium can inuence long-term immune
programming, increasing susceptibility to autoimmune disease. Emerging technologies like gut
organoids and humanized mouse models have provided new insights into the dialogue between the
intestinal barrier and systemic immune cells, offering novel therapeutic targets.
9.2.4 ALTERATION OF IMMUNE CELL DIFFERENTIATION
Another signicant route through which the microbiota modulates autoimmune diseases involves
the alteration of immune cell differentiation. A growing body of evidence highlights that specic
microbial metabolites (particularly SCFAs such as butyrate, propionate, and acetate) play an essential role in determining the fate of T-cell lineages, especially the balance between regulatory Tcells
(Tregs) and pro-inammatory Th17 cells. These metabolites are primarily generated by the fermentation of dietary bers by gut commensal bacteria, including members of the Firmicutes phy-
lum such as F. prausnitzii and Clostridium clusters IV and XIVa. Butyrate, in particular, exerts a
profound immunomodulatory effect by promoting the differentiation of naive CD4+ T cells into
Tregs through epigenetic regulation mechanisms, such as histone acetylation at the Foxp3 promoter
region. This leads to enhanced transcriptional activity of the master regulator gene required for Treg
development. Tregs are crucial for maintaining immune tolerance, suppressing excessive immune
responses, and preventing autoimmune pathology.
In contrast, the absence or signicant depletion of SCFA-producing bacteria (often seen in dysbiotic states associated with autoimmune diseases) can reduce Treg numbers and their suppressive
function. This creates an immunological vacuum in which pro-inammatory pathways can become
dominant. For instance, when benecial SCFAs are lacking, APCs in the gut-associated lymphoid
tissue are more likely to produce IL-6, IL-1β, and IL-23, cytokines that are key drivers of Th17 cell
differentiation. Th17 cells, which are characterized by their production of interleukin-17 (IL-17), are
essential for mucosal defense but are also known to be pathogenic in a variety of autoimmune disorders, including RA, MS, psoriasis, and inammatory bowel disease. This shift in the Treg/Th17
axis due to microbiota imbalance not only facilitates local inammation but may also contribute to
systemic autoimmune activity.
The role of bacterial metabolites extends beyond SCFAs. Another important class includes
tryptophan-derived catabolites produced by commensal bacteria such as Lactobacillus and
Bidobacterium species. These microbial byproducts engage the aryl hydrocarbon receptor (AhR),
Соседние файлы в папке Библиотека им академика М.И. Перельмана